Alpha Cognition (OTC:ACOGF) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Alpha Cognition (OTC:ACOGF) announced its quarterly earnings data on Monday. The company reported C($0.01) EPS for the quarter, beating the consensus estimate of C($0.04) by C$0.03, Yahoo Finance reports.

Alpha Cognition Trading Up 4.5 %

ACOGF traded up C$0.02 during midday trading on Tuesday, hitting C$0.46. 19,119 shares of the company traded hands, compared to its average volume of 74,791. The company has a market capitalization of C$54.38 million, a price-to-earnings ratio of -3.29 and a beta of 2.87. Alpha Cognition has a 52-week low of C$0.16 and a 52-week high of C$0.74. The business has a 50 day simple moving average of C$0.54 and a two-hundred day simple moving average of C$0.55.

Analyst Upgrades and Downgrades

Separately, Raymond James raised shares of Alpha Cognition from a “hold” rating to a “moderate buy” rating in a research report on Monday, July 15th.

Alpha Cognition Company Profile

Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.